|Phase III||Treatment||Completed||18 and over||Pharmaceutical / Industry||EMR 62202-002|
The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with recurrent or metastatic head and neck cancer. Overall survival will be taken as the primary measure of efficacy.
- Histologically or cytologically confirmed diagnosis of squamous cell carcinoma of the head and neck (SCCHN)
- Recurrent and/or metastatic SCCHN, not suitable for local therapy
- Prior systemic chemotherapy, except if given as part of a multimodal treatment for locally advanced disease which was completed more than 6 months prior to study entry
- Surgery (excluding prior diagnostic biopsy), or irradiation within 4 weeks before study entry
- Nasopharyngeal carcinoma
Trial Lead Organizations/Sponsors
Merck and Company, Incorporated
|Jan B. Vermorken, Prof.||Principal Investigator|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00122460
Information obtained from ClinicalTrials.gov on January 10, 2012
Back to Top